PTGS2 and cancer: By CRISPR-mediated ablation of COX-2 or genetic engineering of its transcriptional activity by swapping the regulatory promoter region controlling Ptgs2 transcription, we were able to expose the selective and profound impact of augmented COX-2 activity on the inflammatory properties of CTX-treated cancer cells in vivo.